Chinese Vaccine Industry Association: Resolutely resist disorderly low-price competition and strictly prohibit participating in bids with prices lower than the cost.

In order to actively respond to the national strategic deployment to promote the high-quality development of the biopharmaceutical industry, and to guide the industry's sustainable and healthy development, on November 19, the China Vaccine Industry Association issued the "Proposal to Oppose 'Internal Competition' and Promote High-Quality Development of Vaccines and Related Biologics Industry." It pointed out that all members of the China Vaccine Industry Association must strictly follow the "Vaccine Administration Law of the People's Republic of China" and the "Price Law of the People's Republic of China," strictly adhere to industry self-discipline conventions, adhere to the principles of fairness, legality, honesty, and credit, use production and operation costs and market supply and demand as the basic pricing basis, price independently and reasonably in accordance with the law, consciously maintain market price stability, and jointly create a fair and orderly competitive environment. It firmly opposes disorderly and low-price competition, strictly prohibits participating in bidding with prices below cost throughout the entire bidding process, and effectively guarantees the quality standards of products and services. The China Vaccine Industry Association stated that this proposal aims to strengthen self-regulation, encourage innovation, help the industry to break the "vicious circle," build a healthy and orderly benign ecosystem, and jointly open a new chapter in industry development with quality, safety, and innovation as the core. The full text of the proposal is as follows: Proposal to Oppose "Internal Competition" and Promote High-Quality Development of Vaccines and Related Biologics Industry All members of the China Vaccine Industry Association must strictly follow the "Vaccine Administration Law of the People's Republic of China" and the "Price Law of the People's Republic of China," strictly adhere to industry self-discipline conventions, adhere to the principles of fairness, legality, honesty, and credit, use production and operation costs and market supply and demand as the basic pricing basis, price independently and reasonably in accordance with the law, consciously maintain market price stability, and jointly create a fair and orderly competitive environment. It firmly opposes disorderly and low-price competition, strictly prohibits participating in bidding with prices below cost throughout the entire bidding process, and effectively guarantees the quality standards of products and services. All members should adhere to innovation-driven development, promote the research and development and application of key core technologies and innovative products, and promote the high-quality development of the vaccine and related biologics industry in a healthy and fair competitive environment. After approval by the Council, all members should collectively abide by this proposal and accept industry and social supervision. In case of violation, they will be collectively condemned by all members, and measures such as warning, public criticism, suspension of member rights, and even expulsion will be taken by the association. This article is selected from the WeChat official account of the "China Vaccine Industry Association," edited by GMTEight: Feng Qiuyi.